The response to initial glucocorticoid therapy in childhood acute lymphoblastic leukaemia (ALL) reliably predicts the response to multiagent chemotherapy. Patients resistant to glucocorticoids (prednisone poor responders (PPR)) have a poorer event-free survival compared to glucocorticoid-sensitive patients (prednisone good responders (PGR)). A casecontrol study was performed to investigate differential protein expression in leukaemic blasts from PGR and PPR childhood ALL patients. Two-dimensional gel electrophoresis (2-DE) was used for an unsupervised screening and surface enhanced laser desorption/ionisation-time of flight mass spectrometry (SELDI-TOF MS) for the characterisation of protein spots. In difference maps of average gels for the proteomes of each responder group, differentially expressed proteins were identified after tryptic digestion and spotting onto H4-SELDI-TOF-MS chips. Proteins overexpressed in PPR were Catalase, RING finger protein 22 alpha, Valosin-containing protein (VCP) and a G-protein-coupled receptor. Proteins overexpressed in PGR were protein kinase C and malate dehydrogenase. Valosincontaining protein was chosen for validation and quantification by Western blot analysis in a second case-control group of ALL patients. In this second independent cohort, median VCP expression (P 25 -P 75 ) was 0.15 (0.11-0.28) in PGR and 0.34 (0.14-0.99) in PPR patients (P ¼ 0.04). We conclude that high VCP expression is associated with poor prednisone response in childhood ALL patients.
Introduction
In childhood acute lymphoblastic leukaemia (ALL) treated according to the Berlin-Frankfurt-Mü nster (BFM) protocols, the early in vivo glucocorticoid response has a strong power to predict therapy outcome, because it correlates well with the response to multiagent chemotherapy. [1] [2] [3] [4] The clinical phenomenon assessing early in vivo glucocorticoid response in childhood ALL is called prednisone response (PR), and is defined by the number of peripheral leukaemic blasts after 7 days of prednisone therapy and one intrathecal dose of methotrexate on day one. It is considered as good (prednisone good responders (PGR)) if the peripheral blast count on treatment day 8 is o1000 blasts/ml, whereas it is poor (prednisone poor responders (PPR)) if patients show X1000 blasts/ml. In trial ALL-BFM 90, PGR had an estimated probability of 6 years event-free survival (6y-pEFS) of 82% in contrast to PPR, who showed a 6y-pEFS of only 34%. 3 To better understand the mechanisms underlying glucocorticoid response in ALL, this study aimed at identifying differentially expressed proteins within the proteome of leukaemic cells from PGR and PPR B-cell precursor childhood ALL patients. By analysing whole-cell lysates from leukaemic bone marrow and peripheral blood mononuclear cells and by using the two-dimensional gel electrophoresis (2-DE) as an unsupervised screening method, we ensured that the highest possible number of known and unknown proteins be investigated at one time. Surface enhanced laser desorption/ionisation-time of flight mass spectrometry (SELDI-TOF MS) was chosen for the analysis/ characterisation of the excised protein spots and Western blot analysis for validation of the results.
Materials and methods

Patients and study design
Two independent studies were performed on patients from the ALL-BFM 95 and the ALL-BFM 2000 trials. Both studies had a case-control design with one case matching two controls. The first study was performed as an unsupervised proteome screening (2-DE) and included four PPR (cases) and eight PGR (controls) ALL patients with B-cell precursor immunophenotype. The second study was used for validation of the 2-DE data and used Western blot analysis to semiquantify protein expression of the target proteins. Ten PPR with B-cell precursor immunophenotype and 20 PGR with B-cell precursor immunophenotype were included. Residual archived material (peripheral blood and bone marrow) as well as clinical data from the ALL-BFM 95 and the ALL-BFM 2000 multicentre trials were used. Informed written consent was obtained and the study was approved by local Ethics Committees. Cases were individually matched to two controls. Matching criteria for both patient samples were initial white blood cell count (WBC) category, sex, and age category at diagnosis. White blood cell count categories were defined as o10 000, 10 000 to o100 000 and X100 000 leukocytes/ml; age categories were o1 year, 1-9 years and X10 years ( Table 1 ). The distribution of the t(9;22) (BCR-ABL), t(4;11) (MLL-AF4) and t(12;21) (TEL-AML1) molecular genetic rearrangements within the two responder groups, as tested by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence-in situ-hybridisation, was the same in the 2-DE study group. In the Western blot study group, six cases and no control were positive for the TEL-AML1 rearrangement, the distribution of BCR-ABL and MLL-AF4 molecular rearrangements within the two responder groups was equal (Table 1) .
Cell samples
Samples were taken at diagnosis and before administration of glucocorticoids. In peripheral blood and bone marrow samples, a minimum of 75% leukaemic blasts was mandatory prior to gradient centrifugation. Mononuclear cells were isolated routinely using gradient centrifugation (Ficoll-Paque, Amersham Biosciences, Freiburg, Germany). After isolation, cells were frozen in Roswell park memorial institute medium containing 10% dimethyl sulphoxide and stored in liquid nitrogen.
Protein isolation
Proteins were isolated using a standard protocol for isolation of cytosolic and nuclear proteins. 5 Slight modifications of the protocol included NP40 concentration (0.1% instead of 0.2%), omission of 4-(Z-aminoethyl)benzenesulphonyl fluoride (AEBSF) and an incubation period of 10-30 min at 41C after resuspension into Dignam buffer A. 6 To avoid burning of the precast immobiline dry strip gels during isoelectric focusing (IEF), lysates were deionised using ion exchange columns (Amersham Biosciences) and concentrated by vacuum centrifugation. ), at least two digital photos of each gel with different exposure times were taken and independently analysed with the ImageMaster 2D Elite s software (Amersham Biosciences). The gel with the most spots detectable was chosen as reference gel. Every gel was independently matched to this reference gel. Spots of a gel that could not be matched were added to the reference gel before matching the next gel. After completion of the matching procedure, average gels for PPR and for PGR were created as described in the software handbook of the ImageMaster 2D Elite s software (Amersham Biosciences) Difference maps detecting the presence and absence of spots within both average gels were calculated (Figures 1-3 ). For this Table 1 Distribution of matching criteria of childhood ALL patients 
ALL, acute lymphoblastic leukaemia; 2-DE, two-dimensional gel electrophoresis; PPR, prednisone poor responders; PGR, prednisone good responders; WBC, white blood cell count. Valosin-containing protein in childhood ALL M Lauten et al procedure all spots were analysed, which were present on either the PGR or the PPR average gel. Within the averaging parameters defined within the software, the maximum absences of spots in the primary gels, which have to be defined in the software menu, were set to 'zero'. This ensured that only those spots that were present on all primary gels of PGR or on all primary gels of PPR qualified for evaluation.
Protein characterisation
For characterisation of the differentially expressed proteins, the 2-DE gels were treated with a reversible staining method as described by the manufacturer (E-Zinc Reversible Stain Kit Pierce, Rockford, USA). Briefly, the gel was stained with 40 ml of a zinc staining solution for 10 min. After this, the fluid was replaced by 40 ml developer solution. After 2 min, the gel was checked against a dark background. When protein spots were clearly visible, the developer was replaced by deionised water.
The protein spots of interest were excised with a sterile scalpel and washed two to three times with 25 mM ammonium carbonate in 50% acetonitrile. After drying in a speed vac for 15 min at 301C, gel pieces were incubated for 1 h at 561C in 10 mM DTT (Sigma, Munich, Germany). Dithiothreitol was removed by incubation in a 55 mM iodoacetamide solution for 45 min at 371C in the dark. After three washes with 25 mM ammonium carbonate, the dehydrated gel pieces were dried at 301C for 15 min. After tryptic digestion overnight (trypsin gold in 40 mM NH 4 HCO 3 /10% acetonitrile; Promega, Madison, USA), the supernatant was removed from the gel piece and the gel piece dried under vacuum. The peptides were extracted with 50% acetonitrile and 5% trifluroacetic acid. The concentrated peptides were mixed with 4 ml a-hydroxycinnamic acid (10 mg solution with 70% acetonitrile, 0.3% trifluoroacetic acid) and mixed with 10 fmol of the marker proteins angiotensin (1296 Da) and b-endorphin (3465 Da) for internal calibration. Two microlitres of the mix were spotted onto an H4-protein chip (Ciphergen, Gö ttingen, Germany) and measured in a SELDI-TOF-MS (SELDI-TOF-MS PBS II, Ciphergen, Gö ttingen, Germany).
Known marker proteins from the 2-DE gel and a piece from the spot-free region as negative control were also excised from the gel and processed in the same way to test the reliability of the method.
Peptide spectra were measured between 500 and 5000 Da. At least seven peptides were used to find the corresponding proteins in the ProFound data base 
Western blotting
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed with two gels at a time. Fifteen microgramsof protein from total cell lysate was separated on 10% SDS gels for 90 min at 180 V (Owl Scientific Inc., Woburn, USA). The gels were transferred onto nitrocellulose membranes (Trans-Blot Transfer Medium, BioRad Laboratories, Richmond, USA) and blotted in parallel at 20 V for 2 h. After blotting, gels (Coomassie blue) and membranes (Ponceau S) were stained to document successful blotting. Every gel was loaded with 15 mg protein from HeLa S 3 cells as positive control and with a prestained marker (precision plus protein standard, Bio-Rad Laboratories GmbH, Mü nchen, Germany). The membranes were incubated with a mouse monoclonal anti-VCP antibody (#65278, Progen Biotechnik GmbH, Heidelberg, Germany) at 41C overnight. After washing three times with PBS-T (phosphatebuffered saline with bovine serum albumin), gels were incubated with a goat anti-mouse secondary antibody (sc-2005, SantaCruz Biotechnology) at 211C for 2 h. Subsequently, the membranes were incubated with a mouse monoclonal antib-actin antibody (sc-8432, SantaCruz Biotechnology) at 41C overnight. Washing and incubation with the secondary antibody was performed as described above. Finally, the protein bands were visualised on an X-ray film (Cronex 5, AGFA, Mortsel, Belgium) using the electro-chemoluminescence method, according to the manufacturer's instructions. Bands of VCP appeared at approximately 97 kDa, and bands of b-actin protein at approximately 37 kDa (Figure 4 ). After scanning of the X-ray film, image analysis was performed on a Macintosh iMac computer using the public domain NIH Image program (available under http://rsb.info.nih.gov/nih-image). Two blots of each sample were produced and were within the linear range 
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G3 G4 Figure 3 Difference map showing proteins more often expressed in prednisone good responders. G1 was identified as the protein kinase C b1, and G5 as the malate dehydrogenase 1.
Valosin-containing protein in childhood ALL M Lauten et al established for the antibody using a serial dilution of HeLa S 3 cell proteins.
Statistical analysis
Frequencies were calculated for descriptive purposes. Valosincontaining protein expression was normalised to b-actin expression in HeLa S3 cells. The association between VCP expression and PR was calculated using the Wilcoxon signedrank test for matched pairs. The association between VCP expression and gender or WBC as well as the subgroup analysis was performed using the Mann-Whitney U-test as a nonparametric test for independent variables (Table 2) . Computations were performed using SPSS 13.0 for Windows.
Results
In order to identify differentially expressed proteins, the proteome of 12 B-cell precursor childhood ALL patients was evaluated in a case-control study under strictly standardised conditions. Proteins from whole-cell lysates were separated by 2-DE and subsequently silver-stained. Evaluation of proteome patterns was performed with standard software for the evaluation of 2-DE gels. Proteins with a size range of approximately 20-150 kDa could be reproducibly spotted and analysed. After detection and matching of all spots, strict parameters were set to calculate average proteomes of poor and good prednisone responders. The average number of proteins spotted in PPR was 168; the average number of spots in PGR was 234. The calculation of a proteome difference map from average proteomes of both responder groups identified five proteins, which were more frequently present in patients with PPR than in patients with PGR ( Figure 2 ). Four of the proteins (P2-P5) were identified by tryptic digestion of the respective protein spots, spotting of the peptides onto H4-protein chips and separation in a SELDI-TOF-MS (Supplementary Figure 1) . The peptide fragment pattern was matched to those available in the ProFound database. Proteins overexpressed in PPR were Catalase, RING finger protein 22 alpha, VCP and a G-proteincoupled receptor (family C, group 5, member D (GPRC5D)).
In addition, five proteins were found that were more frequently present in PGR than in PPR (Figure 3 ). Using the SELDI-TOF-MS technology as described above, two of the proteins (G1 and G5) were identified as Protein kinase C b1 and Malate dehydrogenase 1 ( Table 3 ). All of the above-mentioned proteins have been previously described in context with malignancies. [8] [9] [10] [11] [12] [13] From the differentially expressed proteins detected in the PPR group, VCP was chosen to be validated by Western blot analysis, because it is known to mediate apoptosis after tumour necrosis factor (TNF) stimulation by influencing the proteasome degradation pathway.
14 In addition, VCP had already been associated with prognosis in other tumour entities by Yamamoto and co-workers. 10, [15] [16] [17] [18] [19] [20] For the validation, a second independent case-control group was investigated by Western blot analysis. Median VCP expression of all samples in this group was 0.19 (0.12-0.40), whereas PGR showed a median VCP Valosin-containing protein in childhood ALL M Lauten et al expression of 0.15 (0.11-0.28) compared to 0.34 (0.14-0.99) in PPR (P ¼ 0.04). This shows that, in the given subset of B-cell precursor childhood ALL patients, VCP was expressed significantly higher in PPR than in PGR. There was no significant difference in VCP expression between male and female subjects nor between initial WBC categories ( Table 2) .
Discussion
A proteome screening of whole-cell lysates of leukaemic blasts using an unsupervised 2-DE approach was performed aiming at elucidating the biological background of glucocorticoid response in childhood ALL. Until now it has not succeeded in unravelling the cause of GC resistance in various disease entities. Several studies with respect to specific targets like the glucocorticoid receptor (GR) and its splice variants, to proteins involved in the activation process of the GR and genetic variants of drug resistance genes or of the GR itself did not show any correlation between the results and the GC resistance.
21-31
In contrast to many proteome screening studies in human tissues, the advantage of the current study is that proteins were isolated from purified leukaemic cells that had all been processed and stored in the same manner. The minimum percentage of leukaemic blasts in the bone marrow of patients investigated was 77% before gradient centrifugation. Thus, protein contamination, which is one of the most evident problems in the analysis of complex proteomes, should be excluded to a large extent. Additionally, the samples showed an equal distribution of immunphenotypes and molecular aberrations (apart from the biased distribution of TEL-AML1 in the Western blot group). This guaranteed high homogeneity of the samples analysed. Moreover, by using standardised protocols for IEF and SDS-PAGE (commercially available buffer kits and gels in both dimensions) and by software evaluation of the 2-DE gels, the investigator-dependent bias was reduced to a minimum.
However, 2-DE will always also be influenced by investigator-independent variables. One of the leading problems of 2-DE analysis is the 'dynamic range' of relative protein expression, which is suggested to reach 10 5À6 in certain tissues. 32 For all that, 2-DE has become the leading method for the unsupervised analysis of whole-cell lysate proteomes within a size range of 5-130 kDa and a pI range of 4.0-10.5 over the last three decades. 32 A number of differentially expressed proteins were found in this study. All proteins had been previously linked to malignancies and are involved in cellular processes like cell growth (RING finger protein and protein kinase C), regulation of the biological homeostasis including haematopoiesis and immunity (G-protein-coupled receptors), apoptosis (VCP) and processes related to cell division (Malate dehydrogenase). 9, 11, [33] [34] [35] Since quantitative 2-DE was not performed, our results only indicate that these proteins are more frequently present in the average proteome of one responder group. This does not exclude that the respective protein will not be expressed in patients belonging to the other responder group, because proteins with a low expression level, for example, might accidentally escape software recognition. Therefore, a validation of the 2-DE results by Western blot analysis is mandatory to interpret 2-DE data.
In this study, VCP was chosen to be validated, because of its role within the ubiquitin-dependent proteasome degradation pathway and its capability of inhibiting apoptosis after TNF stimulation. 36 In addition, Yamamoto and et al. 14, 37 had shown that VCP may increase the metastatic potential in tumour entities, possibly through interference with the nuclear factor kappa B pathway.
The VCP, the homologue of yeast cdc48p, is a ubiquitous 100 kDa structural protein that is complexed with clathrin and heat-shock protein Hsp70 (OMIM No. 118960). As a member of a protein family that includes putative ATP-binding proteins involved in vesicle transport and fusion, 26S proteasome function, and assembly of peroxisomes, 38 VCP has been implicated in a number of cellular processes that are tightly regulated during mitosis, including homotypic membrane fusion and spindle pole body function. 39 Valosin-containing protein is a key player in the ubiquitin-dependent proteasome degradation pathway. For example, in order to target polyubiquitinated proteins for proteasomal degradation, VCP interacts with polyubiquitin chains through its ND1 domains and acts as a chaperone for polyubiquitinated proteins. Valosin-containing protein associates with the cofactor ubiquitin fusion degradation 1 (Ufd1) to move polyubiquitinated polypeptides from the endoplasmic reticulum membrane into the cytosol for their subsequent degradation by the proteasome. 40 Interaction of ubiquitin with the UT3 domain of the Ufd1 enhances VCPpolyubiquitin binding. 33 Furthermore, it regulates TNF-induced apoptosis and NFkB activation via IkBa degradation.
14 Thus, increased VCP expression in PPR could lead to a decreased apoptosis of leukaemic blasts. In addition, the ability of VCP to form a complex with Hsp70 might lead to a regulatory effect on the cytosolic GR . Hsp70 . Hsp90 heterocomplex and thus might hamper the activation of the glucocorticoid receptor. This would prevent transactivation and/or transrepression of GR responding genes. However, Bachmann et al. 41 recently suggested that the defect leading to GC resistance occurs downstream of ligand binding and nuclear translocation of the GR, namely in the failure of inducing Bim, a proapoptotic BH3-only protein. This is supported by a study by Tissing et al., 42 in which the expression of 11 (co)chaperone molecules of the glucocorticoid receptor was evaluated in ALL patients by real-time PCR. The authors found no relation between the expression of different (co)chaperones and GC resistance.
Our data obtained from this unsupervised study suggest that VCP might indicate a new target protein for GC resistance and later resistance to multiagent chemotherapy in B-cell precursor ALL.
Cario et al. identified differences in gene expression signatures of ALL samples with high minimal residual disease (MRD) load and without measurable MRD load during treatment. They found 54 genes that clearly distinguished resistant from sensitive ALL samples. 43 Valosin-containing protein was investigated as well, but it was not found to be one of the differentially expressed genes in PPR versus PGR patients. However, the patients analysed were stratified according to MRD load during treatment and not matched for PR. Furthermore, post-transcriptional modifications could influence VCP RNA expression, which might then lead to differentially expressed VCP protein. Further studies have to be performed to better define the functional consequences of increased VCP expression on related pathways and to investigate the meaning of the other proteins identified in this study.
Concluding remarks
In a closely matched homogeneous sample set of patients with B-cell precursor childhood ALL, differentially expressed proteins in PPR and PGR patients were identified using the 2-DE as an unsupervised screening method and SELDI-TOF MS for protein characterisation. The results were validated by Western blot analysis using a second independent closely matched patient sample set. Valosin-containing protein expression is associated with GC resistance in B-cell precursor childhood ALL and, therefore, might indicate later multiagent chemotherapy resistance and treatment outcome in childhood ALL patients.
Based on the data obtained in this study, we conclude that VCP expression is significantly higher in PPR than in PGR patients suffering from B-cell precursor childhood ALL. This might be a first hint that GC action may be influenced by cellular pathways that have not been described so far in this context.
